Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate

Curran, Michael J.; Bihrle, William

doi:10.1016/s0090-4295(98)00348-3

Cited by 76 publications

(46 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Undesirable effects related directly to T include acne, prostate disorders (such as benign prostatic hyperplasia), sleep apnea and erythrocytosis. 24 …”

Section: Testosterone Therapy For Hypogonadismmentioning

confidence: 99%

“…24,30 Long time treatment in these age groups can lead to premature closure of the epiphysis and permanent short stature. Acne is found in up to 8% while gynecomastia is found in up to 3%.…”

Section: Dermatologic and Endocrine Side Effectsmentioning

confidence: 99%

mentioning

confidence: 99%

“…16,24,49 As an example, a case of a 85 year old hypogonadal man with occult adenocarcinoma of the prostate showed a rapid rise of PSA after TRT. 24 In a prospective study of 2200 men with hypogonadal symptoms over a period of 15 years, prostate cancer was detected in only 10 patients (0.48% cases/ year). 16 In a 2010 meta-analysis of 51 randomized trials of T therapy in men with the primary endpoints mortality, cardiovascular events and risks, prostate outcomes and erythrocytosis, no significant effects were recorded with regard to an increased incidence of prostate cancer, need for prostate biopsies, increases in PSA, or change in lower urinary tract symptoms when compared to placebo groups.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Topical Testosterone Gel for the Treatment of Male Hypogonadism

Udeoji¹,

Phan²,

Katsiyiannis

et al. 2012

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Objective: This review describes the current knowledge of biological external testosterone (T) application using dermal products for the treatment of late-onset male hypogonadism (LOH). Methods: An English language search of medical literature using Pubmed was conducted between January of 1984 and March of 2012 using the search term 'testosterone gel'. Special emphasis was given to clinical controlled trials and large case studies. Results: We describe the current knowledge on testosterone replacement therapy using gel applications. A reference search revealed 1567 publications; 44 were clinical studies in human patients with male hypogonadism, 80 were reviews, 27 were case reports, and 9 were retrospective studies. Data from the literature and from 20 clinical studies involving human patients were analyzed since they met the inclusion criteria of testosterone gel administration in hypogonadal males. For the purpose of this review, a total number of 2,378 human patients were studied. Overall, biological T administration resulted in improvement of sexual dysfunction and symptoms of metabolic syndrome and represented an effective and safe treatment option for hypogonadal men. Conclusions: Administration of biological T gel appears to represent a valid alternative treatment option for male hypogonadism with a favorite efficacy and safety profile.

show abstract

“…Undesirable effects related directly to T include acne, prostate disorders (such as benign prostatic hyperplasia), sleep apnea and erythrocytosis. 24 …”

Section: Testosterone Therapy For Hypogonadismmentioning

confidence: 99%

Section: Dermatologic and Endocrine Side Effectsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Topical Testosterone Gel for the Treatment of Male Hypogonadism

Udeoji¹,

Phan²,

Katsiyiannis

et al. 2012

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

show abstract

“…The occurrence of prostate cancer after testosterone administration to (elderly) men has been reported [134][135][136][137][138]. By contrast, a variety of studies, using various designs and testosterone formulations, over periods ranging from several months to 15 years, in men with a wide range of ages, have not revealed an increased risk of prostate cancer [139][140][141][142][143][144][145][146][147][148][149][150][151][152][153][154].…”

Section: Lower Urinary Tract Symptoms and Prostate Diseasementioning

confidence: 99%

Androgens and male aging: current evidence of safety and efficacy

Gooren¹

2010

Asian J Androl

View full text Add to dashboard Cite

Many signs of aging, such as sexual dysfunction, visceral obesity, impaired bone and muscle strength, bear a close resemblance to features of hypogonadism in younger men. The statistical decline of serum testosterone in aging men is solidly documented. It has been presumed that the above features of aging are related to the concurrent decline of androgens, and that correction of the lower-than-normal circulating levels of testosterone will lead to improvement of symptoms of aging. But in essence, the pivotal question whether the age-related decline of testosterone must be viewed as hypogonadism, in the best case reversed by testosterone treatment, has not been definitively resolved. Studies in elderly men with lower-than-normal testosterone report improvement of features of the metabolic syndrome, bone mineral density, of mood and of sexual functioning. But as yet there is no definitive proof of the beneficial effects of restoring testosterone levels to normal in elderly men on clinical parameters. Few of these studies meet as yet rigorous standards of scientific enquiry: double-blind, placebo-controlled design of the study. The above applies also to the assessment of safety of testosterone administration to elderly men. There is so far no convincing evidence that testosterone is a main factor in the development of prostate cancer in elderly men and guidelines for monitoring the development of prostate disease have been developed. It is of note that there are presently no long-term safety data with regard to the prostate. Polycythemia is another potential complication of testosterone treatment. It is dose dependent and can be managed with dose adjustment.

show abstract